You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Factors associated with 28-day mortality in patients with P. mirabilis bacteremia

From: The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea

Factors Survivors N = 51 (%) Nonsurvivors N = 11 (%) p value
Age, y, median(IQR) 71.0 (63.0–79.0) 73.0 (54.0–84.0) 0.797
 Age ≥ 65 years, n(%) 32 (62.7) 7 (63.6) 1.000
Sex, male, n(%) 21 (41.2) 6 (54.6) 0.51
BMI, kg/m2, median(IQR) 22.35 (10.07–25.52) 21.78 (19.15–23.29) 0.366
ESBL producing pathogen, yes, n(%) 7 (13.7) 7 (63.6) 0.001
Infection source
 Urinary tract infection, n(%) 28 (54.9) 4 (36.4) 0.264
 Pneumonia, n(%) 6 (11.8) 3 (27.3) 0.191
 Skin and soft tissue infection, n(%) 2 (3.9) 0 (0) 1.000
 Biliary infection, n(%) 8 (15.7) 1 (9.1) 1.000
 Catheter related infection, n(%) 2 (3.9) 1 (9.1) 0.449
Comorbities
 HTN, n(%) 33 (64.7) 5 (45.5) 0.311
 DM, n(%) 21 (41.2) 3 (27.3) 0.505
 Cardiovascular disease, n(%) 5 (9.8) 3 (27.3) 0.142
 Chronic kidney disease, n(%) 7 (13.7) 0 (0) 0.334
 Chronic liver disease, n(%) 3 (5.9) 3 (27.3) 0.063
 Rheumatologic disease, n(%) 2 (3.9) 0 (0) 1.000
 Solid tumor, n(%) 26 (51.0) 6 (54.5) 0.83
 Hematologic malignancy, n(%) 1 (2.0) 1 (9.1) 0.326
 Solid organ transplantation, n(%) 2 (3.9) 1 (9.1) 0.449
 Charlson score, median(IQR) 2.0 (1.0–2.0) 2.0 (1.0–4.0) 0.239
Predisposing factors
 Neutropenia, n(%) 2 (4.0) 0 (0) 1.000
 Chemotherapy, n(%) 7 (13.7) 1 (9.1) 1.000
 Nursing home residence, n(%) 7 (13.7) 0 (0) 0.334
 Hemodialysis, n(%) 8 (15.7) 3 (27.3) 0.394
 Maintaining foley catheter, n(%) 11 (21.6) 6 (54.5) 0.056
 Maintaining PEG tube, n(%) 4 (7.8) 1 (9.1) 1.000
 ICU care, n(%) 13 (25.5) 6 (54.5) 0.077
 Previous antibiotic use, n(%) 13 (25.5) 7 (63.6) 0.029
  Cephalosporins, n(%) 6 (11.8) 2 (18.2) 0.623
  Carbapenems, n(%) 3 (5.9) 1 (9.1) 0.552
  Fluorquinolones, n(%) 1 (2.0) 2 (18.2) 0.079
  BLBLI, n(%) 3 (5.9) 2 (18.2) 0.212
Clinical presentation
 Shock, n(%) 19 (37.3) 4 (36.4) 1.000
 Acute kidney injury, n(%) 14 (27.5) 3 (27.3) 1.000
 APACHE II score, median(IQR) 11.0 (8.0–16.0) 17.0 (11.0–19.0) 0.027
 SOFA score, median(IQR) 2.0 (1.0–5.0) 5.0 (4.0–8.0) 0.033
 Inappropriate antimicrobial therapy, n(%) 10 (19.6) 5 (45.5) 0.115
  1. IQR interquartile range, BMI body mass index, ESBL extended spectrum β-lactamases, HTN hypertension, DM diabetes mellitus, PEG percutaneous endoscopic gastrostomy, ICU intensive care unit, BLBLIs beta-lactam/beta-lactamase inhibitors, APACHE II score Acute Physiology and Chronic Health Evaluation II score, SOFA score the Sequential Organ Failure Assessment score